Forty three Eighteen Advisors LLC Purchases New Holdings in CVS Health Corporation $CVS

Forty three Eighteen Advisors LLC purchased a new stake in CVS Health Corporation (NYSE:CVS) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 8,000 shares of the pharmacy operator’s stock, valued at approximately $635,000.

Several other institutional investors also recently modified their holdings of the company. Swiss RE Ltd. bought a new position in CVS Health in the fourth quarter worth $26,000. Sankala Group LLC bought a new stake in CVS Health in the 4th quarter valued at $28,000. Caitong International Asset Management Co. Ltd raised its stake in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. acquired a new position in shares of CVS Health in the 4th quarter valued at $28,000. Finally, Ares Financial Consulting LLC bought a new position in shares of CVS Health during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is currently owned by corporate insiders.

CVS Health Price Performance

Shares of CVS stock opened at $98.26 on Friday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $102.77. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The firm’s 50 day moving average is $89.31 and its 200-day moving average is $81.48. The firm has a market capitalization of $125.38 billion, a price-to-earnings ratio of 43.29, a PEG ratio of 0.96 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the business earned $2.25 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. TD Cowen raised their price target on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Robert W. Baird increased their target price on CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Wells Fargo & Company raised their target price on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a research note on Thursday, June 11th. Finally, UBS Group upped their price target on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health presently has an average rating of “Moderate Buy” and a consensus price target of $100.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.